We specialize
in rapid development
of a unique
Personalized
mRNA Cancer Immunotherapies
OUR MISSION
Our mission is to develop personalized cancer vaccines designed to direct the immune response of the patient to attack the specific cancer cells of the patient, based on a collection of neoantigens that have been linked with the specific cancer cells of the patient.
MY CANCER IMMUNOTHERAPIES (MCI) ARE PERSONALIZED
TARGETED FOR YOU
Normax mRNA cancer immunotherapy will be manufactured for individuals based on the specific molecular features of their tumors which are called neoantigens. Training your immune system to recognize these neoantigen protein targets on the surface of your cancer cells could empower your body to control your cancer.
PERSONALIZED FOR YOU
For more than a decade, cancer researchers have been developing a type of treatment known as a personalized cancer immunotherapy using various technologies, including mRNA and protein fragments, or peptides to target your neoantigens of your cancer. A personalized mRNA immunotherapy from Normax could be a safe and effective tool for your doctors to use in the arsenal to fight your cancer.
RAPID DELIVERY FOR YOU
Normax plans to produce a personalized mRNA cancer immunotherapies for doctor prescribed patients, after tissue samples have been collected, within 1 to 2 months. Speed is especially important for individualized cancer immunotherapy. Ideally, a highly individualized combination of targets on your neoantigens should be designed and produced within 10 weeks of taking your tumor biopsy and blood sample.
mRNA IMMUNOTHERAPIES ARE SAFE AND CAN BE EFFECTIVE
mRNA VACCINES FOR TREATMENT
The success of mRNA COVID-19 vaccines has helped accelerate clinical research on mRNA vaccines to treat cancer. mRNA Vaccine technology is extremely promising for infectious diseases and can lead to development of vaccines in the treatment of cancer. Dozens of clinical trials are testing mRNA treatment vaccines in people with various types of cancer, including pancreatic cancer, colorectal cancer, and melanoma. Some vaccines are being evaluated in combination with drugs that enhance the body’s immune response to tumors. However, mRNA cancer immunotherapies have yet to be approved by the US Food and Drug Administration for use either alone or with other cancer treatments.
PROTEIN SYNTHESIS
Synthetic mRNA provides a template for the synthesis of any given protein, protein fragment or peptide and lends itself to a broad range of pharmaceutical applications, including different modalities of cancer immunotherapy. With the ease of rapid, large-scale Good Manufacturing Practice-grade mRNA production, mRNA is ideally poised not only for off-the shelf cancer vaccines but also for personalized vaccination for your neoantigens.
IMMUNE RESPONSE
With this approach, researchers try to elicit an immune response against abnormal proteins, your neoantigens, produced by cancer cells. Because these proteins are not found on normal cells, they are promising targets for vaccine-induced immune responses. Personalized cancer vaccines can stimulate the immune system to recognize cancer cells from healthy cells, and kill only the cancer.
mRNA CANCER IMMUNOTHERAPY TECHNOLOGY
CLINICAL TRIALS
MY CANCER IMMUNOTHERAPIES (MCI) by Normax is initiating clinical trial testing of personalized mRNA immunotherapies to target the patient’s unique neoantigens. The goal is a complete and enduring response whereby all signs of the tumor disappear following treatment.
COMPUTER ALGORITHMS
The manufacturing process starts with the identification of genetic mutations in a patient’s tumor cells that could give rise to neoantigens. Computer algorithms then predict which neoantigens are most likely to bind to receptors on T cells and stimulate an immune response.
T CELL ACTIVATION
The immunotherapies can include genetic sequences for many different neoantigens. The promise of personalized immunotherapy with mRNA technology is being able to activate T cells that will specifically recognize individual cancer cells based on their abnormal molecular features.
ABOUT CANCER THERAPY
Types of Cancer Treatment
There are many types of cancer treatment. The types of treatment that you receive will depend on the type of cancer you have and how advanced it is. Some people with cancer will have only one treatment. But most people have a combination of treatments, such as surgery with chemotherapy, radiation therapy and new personalized therapies for optimal outcomes. More days of healthy living is our goal at Normax. Many more days. For You.
Surgery
When used to treat cancer, surgery is a procedure in which a surgeon removes cancer from your body.
Chemotherapy
Chemotherapy is a type of cancer treatment that uses drugs to kill cancer cells.
Radiation Therapy
Radiation therapy is a type of cancer treatment that uses high doses of radiation to kill cancer cells and shrink tumors.
Biomarker testing for cancer treatment is a way to look for genes, proteins, and other substances (called biomarkers or tumor markers) that can provide information about cancer.
Immunotherapy
Immunotherapy is a type of cancer treatment that helps your immune system fight cancer.
Hyperthermia is a type of treatment in which body tissue is heated to as high as 113 °F to help damage and kill cancer cells with little or no harm to normal tissue.
Hormone Therapy
Hormone therapy is a treatment that slows or stops the growth of breast and prostate cancers that use hormones to grow.
Photodynamic Therapy
Photodynamic therapy uses a drug activated by light to kill cancer and other abnormal cells.
Stem Cell Transplant
Stem cell transplants are procedures that restore stem cells that grow into blood cells in people who have had theirs destroyed by high doses of chemotherapy or radiation therapy.
Targeted Therapy
Targeted therapy is a type of cancer treatment that targets the changes in cancer cells that help them grow, divide, and spread.
mRNA IMMUNOTHERAPY DEVELOPMENT
mRNA VACCINE CONSORTIUM
Normax assembled the mRNA UCV Consortium, founded for the development and delivery of mRNA Vaccines for COVID-19. The mRNA UCV Consortium comprises over 25 members working in synergy: biomedical industry leaders, engineering specialists and financial experts.
Members of the mRNA UCV Consortium are collaborating to deliver the future of Pandemic Preparedness with mRNA Vaccines for Infectious Diseases.
mRNA VACCINE MANUFACTURING FOR MCI
Introduction to the MCI Center
MCI investigational mRNA cancer immunotherapies will be manufactured for individuals based on the specific molecular features of their tumors which are called neoantigens. Training the patient’s immune system to recognize these neoantigen protein targets on the surface of the patient’s cancer cells could empower the patient’s body to control the patient’s cancer.
Modular Pre-fab Construction
Each MCI CENTER will be a modular construction, made of prefabricated containers to suit the needs of both the medical personnel working there on a daily basis, and the patients requiring medical attention.
ABOUT NORMAX
NormaxBio Inc. is an mRNA Cancer Vaccine development and manufacturing company in USA with subsidiary operations planned in Ireland, Belgium, California, Dubai, France, Luxembourg, Norway, Singapore, Switzerland and the United Kingdom. Normax is leading the mRNA Vaccine Consortium, Vaxcomm, UKvax Factory and USvax Factory plans.